Quoin Pharma forms Japan subsidiary to advance QRX003 commercialization
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
June 18, 2026 8:30 AM EDTSupports Quoins planned direct commercialization of QRX003 in Japan, one of its three core commercial territories
Follows recent grant of Orphan Drug Designation to QRX003 by Japans MHLW
ASHBURN, Va., June 18, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (Quoin or the Company), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part of its strategy to directly commercialize QRX003 for the treatment of Netherton Syndrome, if approved. The formation... More
